To better understand the underlying mechanism for the LCC-09-mediated reduction in GBM cell viability, clonogenicity, and migration, using Western blot assays, we evaluated the expression of our selected panel of oncogenic proteins, and observed that 3 μM LCC-09 significantly reduced the expression level of DRD4 protein, and this was associated with the concurrent downregulation of β-catenin, Akt, mTOR, Erk1/2, p-Erk1/2, NF-κB, c-Myc, and CDK6 protein expression levels (Figure 3D, see also Supplementary Figure S3). The gene discussed is MTOR; the disease is glioblastoma.